Shashank R. Pinnapireddy

Has grant

Head of Nanoparticle Research

Country flagGermany

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Shashank R. Pinnapireddy serves as the Head of Nanoparticle Research at CSL Behring in Germany. His research focuses on innovative drug delivery systems, including the application of lipopolyplexes and nanoparticles in cancer therapy and anti-inflammatory treatments. Recent publications highlight his work on photoselective gene transfection and bioactive compounds for targeted therapies. He continues to advance the field through the exploration of various nanocarrier technologies and their efficacy in medical applications.

Recent Grants

Grant: Close

siRNA Therapy of HPV induced head and neck carcinomas

Open Date: 2019-04-01

Close Date: 2019-04-01

Grant: Close

Composite nanocarriers for gene delivery

Open Date: 2018-09-01

Close Date: 2018-09-01

Grant: Close

Radio-Gene Therapy of head and neck carcinomas

Open Date: 2018-04-01

Close Date: 2018-04-01

Articles (10)

Year:

2024

The cottontail rabbit papillomavirus (CRPV)-associated VX2 carcinoma of the New Zealand White rabbit serves as a model system for human papillomavirus (HPV)-associated head and neck squamous cell carcinomas (HNSCCs). The aim of this study was to evaluate the tumor-inhibiting effect of RNAi-mediated knockdown of the CRPV oncogenes, E6 and E7, using siRNA-loaded lipopolyplexes (LPPs). VX2-carcinoma-derived cells were cultured for up to 150 passages. In addition, CRPV E6 and E7 oncogenes were transiently expressed in COS-7 cells. Efficiency and safety of LPPs were evaluated in both VX2 cells and the COS-7 cell line. Both of these in vitro CRPV systems were validated and characterized by fluorescence microscopy, Western blot, and RT-qPCR. Efficient knockdown of CRPV E6 and E7 was achieved in VX2 cells and COS-7 cells pretransfected with CRPV E6 and E7 expression vectors. Knockdown of CRPV oncogenes in VX2 cells resulted in reduced viability, migration, and proliferation and led to a G0/G1 block in the cell cycle. CRPV E6 and E7 siRNA-loaded LPPs could represent promising therapeutic agents serving as a paradigm for the treatment of papillomavirus-positive cancers and could be of value for the treatment of CRPV-associated diseases in the rabbit such as papillomas and cancers of the skin.

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

Robert Mandic

University Hospital Marburg

GERMANY
View details

Michaela Schulz-Siegmund

Professorin, W3

Leipzig University

GERMANY
View details

Christian Wölk

-

GERMANY
View details

Richard Harvey

Universität Wien

AUSTRIA
View details

Michael Bette

Associated Professor

Philipps-Universität Marburg

GERMANY
View details

Manfred Ogris

Universität Wien

AUSTRIA
View details

Udo Bakowsky

University of Marburg

GERMANY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.